C
CERVOMED INC.
NASDAQ: CRVO (CervoMed Inc.)
Kemas kini terakhir: 18 jam lalu9.62
0.30 (3.22%)
| Penutupan Terdahulu | 9.32 |
| Buka | 9.41 |
| Jumlah Dagangan | 117,597 |
| Purata Dagangan (3B) | 355,655 |
| Modal Pasaran | 89,011,168 |
| Harga / Buku (P/B) | 2.45 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Aug 2025 - 11 Aug 2025 |
| Margin Keuntungan | -200.58% |
| Margin Operasi (TTM) | -276.55% |
| EPS Cair (TTM) | -2.17 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -18.30% |
| Nisbah Semasa (MRQ) | 9.78 |
| Aliran Tunai Operasi (OCF TTM) | -19.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -11.99 M |
| Pulangan Atas Aset (ROA TTM) | -56.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -93.42% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | CervoMed Inc. | Menaik | Menurun |
AISkor Stockmoo
0.6
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.63 |
|
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 33.38% |
| % Dimiliki oleh Institusi | 26.31% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Avantax Advisory Services, Inc. | 30 Jun 2025 | 26,087 |
| Cornerstone Wealth Management, Llc | 30 Jun 2025 | 17,850 |
| Perigon Wealth Management, Llc | 30 Jun 2025 | 17,306 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 31.00 (D. Boral Capital, 222.25%) | Beli |
| Median | 21.50 (123.49%) | |
| Rendah | 15.00 (Chardan Capital, 55.93%) | Beli |
| Purata | 22.25 (131.29%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 9.29 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 18 Aug 2025 | 31.00 (222.25%) | Beli | 9.83 |
| 11 Aug 2025 | 15.00 (55.93%) | Beli | 9.50 | |
| Roth Capital | 12 Aug 2025 | 16.00 (66.32%) | Beli | 9.40 |
| Chardan Capital | 11 Aug 2025 | 15.00 (55.93%) | Beli | 9.50 |
| Canaccord Genuity | 29 Jul 2025 | 27.00 (180.67%) | Beli | 8.42 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |